Griesshammer, Martin
Saydam, Guray
Palandri, Francesca
Benevolo, Giulia
Egyed, Miklos
Callum, Jeannie
Devos, Timothy
Sivgin, Serdar
Guglielmelli, Paola
Bensasson, Caroline
Khan, Mahmudul
Ronco, Julian Perez
Passamonti, Francesco
Funding for this research was provided by:
Novartis
Article History
Received: 30 April 2018
Accepted: 7 May 2018
First Online: 27 May 2018
Compliance with ethical standards
: The study was approved by the central ethics committee or institutional review board at each participating institution and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.
: MG has participated in speakers bureaus and received honoraria from Novartis, Shire, and AOP Orphan. FPas has participated in speakers bureaus and advisory boards for Novartis and has received honoraria from Novartis. TD has received consultancy fees from Gilead, Novartis, and Janssen and has participated in advisory boards for Novartis, Gilead, and Janssen. JC has received research support for speaking for Novartis at hematology rounds. AMV has received research funding and participated in advisory boards for Novartis and has participated in speakers bureaus for Novartis and Shire. JPR, CB, and MK are employees of Novartis. GS has participated in speakers bureaus for Novartis, has received research funding and honoraria from Novartis, and has received honoraria from Celgene, Bristol-Myers Squibb, and Gilead. Fpal has received honoraria from Novartis. ME, PG, SS, and GB have nothing to disclose.